Quinazoline compound
US10556906B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2019 |
| Grant date | Feb 11, 2020 |
| Priority date | — |
| Expiry date | Jun 5, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
[Problem]Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer.[Means for Solution]The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.